If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 1 - 10 of 190

A Randomized Phase III Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma

This study is being done to answer the following question:
Is it necessary to continue the study drug zanubrutinib once remission has been retained?
We are doing this study because we want to find out if this approach is better or worse than the usual approach for your mantle cell lymphoma. The usual approach is defined as care most people get for previously untreated mantle cell lymphoma.
Protocol No
ALLIANCE-A052101

A Multicentre, Phase II, Randomised, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination with Venetoclax and Rituximab in Participants with Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)

This project is being done to learn more about the safety and efficacy of Acalabrutinib, when given in combination with Venetoclax and Rituximab (AVR), to participants with previously untreated mantle cell lymphoma (MCL).
Protocol No
AZ-D822GC00001-TRAVERSE

A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS with IPSS-R Very Low-, Low-, or Intermediate-risk Who Require RBC Transfusions (MAXILUS)

This project is being done to learn more about Luspatercept if administrated at the maximum approved starting dose to assess that a quicker benefit can be seen in your transfusion burden and hemoglobin level.

Protocol No
BMS-CA0561060

An Open-Label, Multi-Center, Single-Arm Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients with Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

This project is being done to evaluate the safety and tolerability of glofitamab-polatuzumab-R-CHP in patients newly diagnosed DLBCL and determine if a blood test that measures MRD can identify patients most likely to benefit from this regimen.
Protocol No
DFCI-22-606